HIF2α silencing reverts both lipid and CD36 content accumulation in hypoxic hepatocytes and in livers from a murine experimental model which displays NAFLD features due to an overexpression of HIF1 and HIF2. The gene discussed is HIF1A; the disease is metabolic dysfunction-associated steatotic liver disease.